Pierre Krolak-Salmon
Overview
Explore the profile of Pierre Krolak-Salmon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
2230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dauphinot V, Calvi S, Moutet C, Xie J, Dautricourt S, Batsavanis A, et al.
Alzheimers Res Ther
. 2024 Sep;
16(1):198.
PMID: 39238042
Background: The Clinical Dementia Rating (CDR) scale allows to detect the presence of dementia and to assess its severity, however its evaluation requires a significant time (45 min). We evaluated...
2.
Reallon E, Gervais F, Moutet C, Dauphinot V, Desnavailles P, Novais T, et al.
Alzheimers Res Ther
. 2024 Aug;
16(1):195.
PMID: 39210400
No abstract available.
3.
Havreng-Thery C, Oquendo B, Zolnowski-Kolp V, Krolak-Salmon P, Bertin-Hugault F, Lafuente-Lafuente C, et al.
Alzheimers Res Ther
. 2024 Aug;
16(1):178.
PMID: 39103973
No abstract available.
4.
Dauphinot V, Laurent M, Prodel M, Civet A, Vainchtock A, Moutet C, et al.
Alzheimers Res Ther
. 2024 Jul;
16(1):166.
PMID: 39061107
Background: The identification of factors involved in the conversion across the different Alzheimer's disease (AD) stages is crucial to prevent or slow the disease progression. We aimed to assess the...
5.
Krolak-Salmon P, Swerdlow R, Mastain T, Dive-Pouletty C, Pooley N, Kisomi M
Nutr Rev
. 2024 Jul;
83(3):e1034-e1048.
PMID: 39047293
Context: Mild neurocognitive disorder (NCD), formally known as mild cognitive impairment, is usually the clinical stage preceding the development of Alzheimer's disease (AD), the most prevalent major NCD, and other...
6.
Reallon E, Gervais F, Moutet C, Dauphinot V, Desnavailles P, Novais T, et al.
Alzheimers Res Ther
. 2024 Jul;
16(1):163.
PMID: 39044289
Background: Long-term exposure to anticholinergic and sedative drugs could be a modifiable risk factor for cognitive decline. The objective of this study was to measure the association between previous cumulative...
7.
Havreng-Thery C, Oquendo B, Zolnowski-Kolp V, Krolak-Salmon P, Bertin-Hugault F, Lafuente-Lafuente C, et al.
Alzheimers Res Ther
. 2024 May;
16(1):117.
PMID: 38812028
Background: A large proportion of nursing home (NH) residents suffer from dementia and effects of conventional anti-dementia drugs on their health is poorly known. We aimed to investigate the associations...
8.
Novais T, Reallon E, Martin J, Barral M, Krolak-Salmon P, Coste M, et al.
Int J Clin Pharm
. 2024 Apr;
46(4):889-898.
PMID: 38642248
Background: In older patients, medication exposure [i.e. polypharmacy, potentially inappropriate medications (PIMs), medications with anticholinergic and/or sedative properties] is a modifiable risk factor associated with cognitive iatrogenic risk and dementia....
9.
Muller C, Metais A, Boublay N, Breuil C, Daligault S, Di Rienzo F, et al.
J Sports Sci
. 2024 Apr;
42(5):392-403.
PMID: 38574326
When applied over the primary motor cortex (M), anodal transcranial direct current stimulation (a-tDCS) could enhance the effects of a single motor imagery training (MIt) session on the learning of...
10.
Nicolas G, Zarea A, Lacour M, Quenez O, Rousseau S, Richard A, et al.
Genet Med
. 2024 Jan;
26(5):101082.
PMID: 38281098
Purpose: To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD). Methods: We included 700 patients...